• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亨廷顿病症状进展时脑脊液中脑啡肽原减少。

Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease.

机构信息

Department of Neuroscience; Neurology, Uppsala University, Uppsala, Sweden.

Institute of Neuroscience and Physiology; Clinical Neuroscience, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

出版信息

Mov Disord. 2021 Feb;36(2):481-491. doi: 10.1002/mds.28391. Epub 2020 Nov 28.

DOI:10.1002/mds.28391
PMID:33247616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7984171/
Abstract

OBJECTIVE

Identifying molecular changes that contribute to the onset and progression of Huntington's disease (HD) is of importance for the development and evaluation of potential therapies.

METHODS

We conducted an unbiased mass-spectrometry proteomic analysis on the cerebrospinal fluid of 12 manifest HD patients (ManHD), 13 pre-manifest (preHD), and 38 controls. A biologically plausible and significant possible biomarker was validated in samples from a separate cohort of patients and controls consisting of 23 ManHD patients and 23 controls.

RESULTS

In ManHD compared to preHD, 10 proteins were downregulated and 43 upregulated. Decreased levels of proenkephalin (PENK) and transthyretin were closely linked to HD symptom severity, whereas levels of 15 upregulated proteins were associated with symptom severity. The decreased PENK levels were replicated in the separate cohort where absolute quantitation was performed.

CONCLUSIONS

We hypothesize that declining PENK levels reflect the degeneration of medium spiny neurons (MSNs) that produce PENK and that assays for PENK may serve as a surrogate marker for the state of MSNs in HD. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

摘要

目的

鉴定导致亨廷顿病(HD)发病和进展的分子变化对于潜在治疗方法的开发和评估很重要。

方法

我们对 12 名显性亨廷顿病(ManHD)患者、13 名前期(preHD)和 38 名对照组的脑脊液进行了无偏质谱蛋白质组学分析。在由 23 名 ManHD 患者和 23 名对照组组成的另一个队列的样本中,验证了一个具有生物学意义且显著的可能生物标志物。

结果

与 preHD 相比,ManHD 中有 10 种蛋白下调,43 种蛋白上调。前脑啡肽(PENK)和转甲状腺素水平降低与 HD 症状严重程度密切相关,而 15 种上调蛋白的水平与症状严重程度相关。在进行绝对定量的另一个队列中,复制了 PENK 水平降低的现象。

结论

我们假设 PENK 水平的下降反映了产生 PENK 的中型棘突神经元(MSNs)的退化,并且 PENK 测定可能作为 HD 中 MSNs 状态的替代标志物。 © 2020 作者。运动障碍由 Wiley Periodicals LLC 代表国际帕金森和运动障碍协会出版。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e87/7984171/99a4f6231e07/MDS-36-481-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e87/7984171/dc6d96a1fbfb/MDS-36-481-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e87/7984171/90d86c1925c6/MDS-36-481-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e87/7984171/99a4f6231e07/MDS-36-481-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e87/7984171/dc6d96a1fbfb/MDS-36-481-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e87/7984171/90d86c1925c6/MDS-36-481-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e87/7984171/99a4f6231e07/MDS-36-481-g001.jpg

相似文献

1
Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease.亨廷顿病症状进展时脑脊液中脑啡肽原减少。
Mov Disord. 2021 Feb;36(2):481-491. doi: 10.1002/mds.28391. Epub 2020 Nov 28.
2
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease.亨廷顿病和帕金森病患者脑脊液中脑啡肽原和强啡肽原水平的改变不同。
J Neurol. 2022 Sep;269(9):5136-5143. doi: 10.1007/s00415-022-11187-8. Epub 2022 Jun 23.
3
Cerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease.亨廷顿舞蹈病患者脑脊液中前强啡肽衍生肽水平降低。
Mov Disord. 2021 Feb;36(2):492-497. doi: 10.1002/mds.28300. Epub 2020 Oct 2.
4
Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease.与β淀粉样蛋白不同,脑脊液中的胶质纤维酸性蛋白与亨廷顿舞蹈症的疾病症状相关。
J Neurol Sci. 2024 Apr 15;459:122979. doi: 10.1016/j.jns.2024.122979. Epub 2024 Mar 30.
5
Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children.神经丝轻蛋白作为儿童亨廷顿病潜在的血液生物标志物。
Mov Disord. 2022 Jul;37(7):1526-1531. doi: 10.1002/mds.29027. Epub 2022 Apr 18.
6
Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.泛素:亨廷顿舞蹈症中一种潜在的脑脊液进展标志物。
Eur J Neurol. 2015 Oct;22(10):1378-84. doi: 10.1111/ene.12750. Epub 2015 Jun 13.
7
Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial.亨廷顿病预后指数评分在症状前临床试验中的效用。
Mov Disord. 2022 May;37(5):1040-1046. doi: 10.1002/mds.28944. Epub 2022 Feb 16.
8
Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.亨廷顿舞蹈症患者脑脊液中的神经肽Y(NPY):NPY水平升高及NPY1-30片段的差异降解
J Neurochem. 2016 Jun;137(5):820-37. doi: 10.1111/jnc.13624.
9
Decrease in a proenkephalin peptide in cerebrospinal fluid in Huntington's disease and progressive supranuclear palsy.亨廷顿舞蹈病和进行性核上性麻痹患者脑脊液中前脑啡肽原肽水平降低。
Brain Res. 1989 Feb 13;479(2):397-401. doi: 10.1016/0006-8993(89)91648-x.
10
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.拉喹莫德可抑制亨廷顿舞蹈病患者髓样细胞中过度活跃的细胞因子生成。
J Neurochem. 2016 Jun;137(5):782-94. doi: 10.1111/jnc.13553. Epub 2016 Apr 5.

引用本文的文献

1
Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis.脑脊液的肽组学分析揭示了肌萎缩侧索硬化症的新生物标志物候选物。
EMBO Mol Med. 2025 Jul 18. doi: 10.1038/s44321-025-00272-w.
2
Natural products proposed for the management of Huntington's disease (HD): a comprehensive review.用于治疗亨廷顿舞蹈症(HD)的天然产物:全面综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 17. doi: 10.1007/s00210-025-04444-w.
3
Advances in Huntington's Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review.

本文引用的文献

1
Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.脑啡肽原,阿片系统替代物,作为心力衰竭的新型全面肾功能标志物。
Circ Heart Fail. 2019 May;12(5):e005544. doi: 10.1161/CIRCHEARTFAILURE.118.005544.
2
Targeting Huntingtin Expression in Patients with Huntington's Disease.靶向亨廷顿病患者的亨廷顿蛋白表达。
N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. Epub 2019 May 6.
3
Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease.
亨廷顿舞蹈症生物标志物的进展:十年文献计量分析与综合综述
Biology (Basel). 2025 Jan 26;14(2):129. doi: 10.3390/biology14020129.
4
A Pilot Proteomic Analysis of Huntington's Disease by Functional Capacity.基于功能能力的亨廷顿舞蹈病蛋白质组学初步分析
Brain Sci. 2025 Jan 16;15(1):76. doi: 10.3390/brainsci15010076.
5
Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis.在亨廷顿病临床运动诊断前数十年,血液中的体细胞CAG重复序列扩增与神经退行性变的生物标志物相关。
Nat Med. 2025 Mar;31(3):807-818. doi: 10.1038/s41591-024-03424-6. Epub 2025 Jan 17.
6
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.血浆和脑脊液神经丝轻链浓度升高在亨廷顿病小鼠的大脑中响应于突变亨廷顿蛋白降低而稳定。
Transl Neurodegener. 2024 Oct 8;13(1):50. doi: 10.1186/s40035-024-00443-8.
7
Long Neuro-COVID-19: Current Mechanistic Views and Therapeutic Perspectives.长新冠:当前的发病机制观点和治疗展望。
Biomolecules. 2024 Aug 28;14(9):1081. doi: 10.3390/biom14091081.
8
Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment.三例慢性强迫症患者报告在接受利妥昔单抗治疗后,幸福感和功能得到改善。
Mol Psychiatry. 2025 Apr;30(4):1396-1406. doi: 10.1038/s41380-024-02750-y. Epub 2024 Sep 21.
9
Insights into the Pathobiology of GM1 Gangliosidosis from Single-Nucleus Transcriptomic Analysis of CNS Cells in a Mouse Model.从 GM1 神经节苷脂贮积症小鼠模型中枢神经系统细胞的单细胞转录组分析中获得的对其病理生物学的深入了解。
Int J Mol Sci. 2024 Sep 8;25(17):9712. doi: 10.3390/ijms25179712.
10
Exploring Huntington's Disease Diagnosis via Artificial Intelligence Models: A Comprehensive Review.通过人工智能模型探索亨廷顿舞蹈症诊断:全面综述
Diagnostics (Basel). 2023 Dec 3;13(23):3592. doi: 10.3390/diagnostics13233592.
脑脊液中 sCD27 的测量可识别出患有神经炎症性疾病的患者。
J Neuroimmunol. 2019 Jul 15;332:31-36. doi: 10.1016/j.jneuroim.2019.03.015. Epub 2019 Mar 25.
4
The prevalence and the burden of pain in patients with Huntington disease: a systematic review and meta-analysis.亨廷顿病患者疼痛的患病率和负担:系统评价和荟萃分析。
Pain. 2019 Apr;160(4):773-783. doi: 10.1097/j.pain.0000000000001472.
5
Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects.通过对亨廷顿病患者脑脊液的生化特征分析揭示酪氨酸和苯丙氨酸代谢途径的改变。
Sci Rep. 2019 Mar 11;9(1):4129. doi: 10.1038/s41598-019-40186-5.
6
Therapeutic approaches to Huntington disease: from the bench to the clinic.亨廷顿病的治疗方法:从实验室到临床。
Nat Rev Drug Discov. 2018 Oct;17(10):729-750. doi: 10.1038/nrd.2018.133. Epub 2018 Sep 21.
7
Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.脑脊液 sCD27 水平表明在亨廷顿病前期存在 T 细胞介导的炎症活动。
PLoS One. 2018 Feb 23;13(2):e0193492. doi: 10.1371/journal.pone.0193492. eCollection 2018.
8
Novel Modulators of the Growth Hormone - Insulin-Like Growth Factor Axis: Pregnancy-Associated Plasma Protein-A2 and Stanniocalcin-2.生长激素 - 胰岛素样生长因子轴的新型调节剂:妊娠相关血浆蛋白 - A2和鲟钙蛋白 - 2。
J Clin Res Pediatr Endocrinol. 2017 Dec 30;9(Suppl 2):1-8. doi: 10.4274/jcrpe.2017.S001. Epub 2017 Dec 27.
9
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.运动、认知和功能衰退是早期亨廷顿舞蹈症单一进展因素的组成部分。
Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.
10
Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?Tau蛋白还是神经丝轻链——哪种是更适合亨廷顿舞蹈症的生物标志物?
PLoS One. 2017 Feb 27;12(2):e0172762. doi: 10.1371/journal.pone.0172762. eCollection 2017.